•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.MetLife, Inc. (MET) Presents at Morgan Stanley US Financials Conference 2026 Transcript
Lincoln National vs. MetLife: Which Financial Stock Is a Better Buy in 2026?
MetLife: Not Exciting, But It Works
These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
MetLife Inc (MET) Shares Surge 3.1% -- What GF Score of 77 Tells Investors
MetLife CFO to Speak at Morgan Stanley US Financials Conference
Here's Why Investors Should Stay Neutral on MetLife Stock for Now
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
Ares Marks Eagle Football Debt To 16 Cents As MetLife Pushes Back
MetLife Expands Guaranteed Retirement Income Offering with Innovative Flexible Annuity Option
MetLife: Time To Go Long The Common Shares And 6.35% Yielding Preferreds
MetLife Declares Second Quarter 2026 Preferred Stock Dividends
These 2 Finance Stocks Could Beat Earnings: Why They Should Be on Your Radar
MetLife and Global Citizen Launch “Footwork for Futures” Social Media Challenge to Help Expand Access to Education and Sports
MetLife Q1 Earnings Call Highlights
MET Tops Q1 EPS Estimates on Strong Investment Income and Volume Growth
MetLife, Inc. (MET) Q1 2026 Earnings Call Transcript
MetLife (MET) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates